GSK

5 FDA approval decisions to watch in the 3rd quarter
5 FDA approval decisions to watch in the 3rd quarter
BioPharma Dive
FDA
Gilead Sciences
filgotinib
rheumatoid arthritis
GSK
belantamab mafodotin
Multiple Myeloma
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
Flag link:
The first round of Covid-19 vaccines is ‘highly unlikely to be a magic bullet,’ Medicago CEO says
The first round of Covid-19 vaccines is ‘highly unlikely to be a magic bullet,’ Medicago CEO says
Stat
Medicago
GSK
Dynavax
vaccines
COVID-19
Flag link:
AstraZeneca, Lilly, Sanofi and others raise prices to start July: report
AstraZeneca, Lilly, Sanofi and others raise prices to start July: report
Fierce Pharma
AstraZeneca
Eli Lilly
Sanofi
drug pricing
GSK
Biogen
Flag link:
GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada
GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada
Endpoints
GSK
Gilead Sciences
ViiV Healthcare
HIV
cabotegravir
Truvada
Flag link:
GSK, Medicago Forge Agreement to Develop Novel Adjuvanted COVID-19 Vaccine
GSK, Medicago Forge Agreement to Develop Novel Adjuvanted COVID-19 Vaccine
BioSpace
GSK
Medicago
pandemic
COVID-19
vaccines
pandemic adjuvant system
Flag link:
GSK snags first-in-class FDA nod for Rukobia to treat HIV patients who have few options
GSK snags first-in-class FDA nod for Rukobia to treat HIV patients who have few options
Fierce Pharma
GSK
ViiV Healthcare
Rukobia
fostemsavir
HIV
FDA
Flag link:
GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report
GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report
Pharmaforum
GSK
Sanofi
UK
vaccines
COVID-19
pandemic
Flag link:
Go or no go? Pandemic looms over FDA timelines
Go or no go? Pandemic looms over FDA timelines
EP Vantage
Jazz Pharma
Gilead Sciences
Galapagos
GSK
FDA
pandemic
COVID-19
Flag link:
GSK’s kidney disease anemia drug approved in Japan, taking on Astellas’ rival
GSK’s kidney disease anemia drug approved in Japan, taking on Astellas’ rival
Pharmaforum
GSK
anemia
chronic kidney disease
daprodustat
Japan
Astellas
Kyowa Kirin
Flag link:
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
MedCity News
belantamab mafodotin
GSK
Multiple Myeloma
FDA
advisory panels
Flag link:
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August
Fierce Biotech
GSK
Dynavax
Clover BioPharmaceuticals
vaccines
COVID-19
Flag link:
GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya
GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya
Fierce Biotech
GSK
cancer
R&D
oncology
Ideaya
genome editing
Flag link:
GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
Xconomy
GSK
oncology
Zejula
niraparib
belantamab mafodotin
dostarlimab
immuno-oncology
Flag link:
The coronavirus vaccine frontrunners have emerged. Here's where they stand
The coronavirus vaccine frontrunners have emerged. Here's where they stand
BioPharma Dive
COVID-19
vaccines
Moderna Therapeutics
Cansino Biologics
Pfizer
BioNTech
Novavax
Inovio
Oxford BioMedica
AstraZeneca
Merck
JNJ
Sanofi
GSK
Flag link:
Is Moderna Really the Leader in the COVID-19 Vaccine Race?
Is Moderna Really the Leader in the COVID-19 Vaccine Race?
Motley Fool
vaccines
COVID-19
Moderna Therapeutics
AstraZeneca
Pfizer
JNJ
BioNTech
Merck
Sanofi
GSK
Novavax
Inovio
Flag link:
Biotech GSK's cell therapy R&D lead jumps ship to partner Immatics
Biotech GSK's cell therapy R&D lead jumps ship to partner Immatics
Fierce Biotech
GSK
R&D
Immatics
Flag link:
GlaxoSmithKline aims to make 1B doses of vaccine booster for multiple COVID-19 partners
GlaxoSmithKline aims to make 1B doses of vaccine booster for multiple COVID-19 partners
Fierce Pharma
GSK
vaccines
COVID-19
drug manufacturing
Sanofi
pandemic
Flag link:
GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight
GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight
Endpoints
GSK
ASCO 2020
antibody-drug conjugate
belantamab mafodotin
Multiple Myeloma
Flag link:
GSK's asthma drug Nucala gets speedy review for rare blood disorder
GSK's asthma drug Nucala gets speedy review for rare blood disorder
Endpoints
GSK
FDA
Nucala
hypereosinophilic syndrome
HES
priority review
Flag link:
GSK inks $231M manufacturing deal as Hal Barron anticipates fruitful year for pruned R&D group
GSK inks $231M manufacturing deal as Hal Barron anticipates fruitful year for pruned R&D group
Endpoints
GSK
R&D
Hal Barron
Samsung BioLogics
Flag link:

Pages